Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Epidemiological and genomic investigation of chikungunya virus in Rio de Janeiro state, Brazil, between 2015 and 2018.
Moreira FRR, Menezes MT, Salgado-Benvindo C, Whittaker C, Cox V, Chandradeva N, Paula HHS, Martins AF, Chagas RRD, Brasil RDV, Cândido DDS, Herlinger AL, Ribeiro MO, Arruda MB, Alvarez P, Tôrres MCP, Dorigatti I, Brady O, Voloch CM, Tanuri A, Iani F, Souza WM, Cardozo SV, Faria NR, Aguiar RS. Moreira FRR, et al. Among authors: torres mcp. PLoS Negl Trop Dis. 2023 Sep 28;17(9):e0011536. doi: 10.1371/journal.pntd.0011536. eCollection 2023 Sep. PLoS Negl Trop Dis. 2023. PMID: 37769008 Free PMC article.
Predictors of non-transplantable recurrence in hepatocellular carcinoma patients treated with frontline liver resection.
Pelizzaro F, Trevisani F, Simeon V, Vitale A, Cillo U, Piscaglia F, Missale G, Sangiovanni A, Foschi FG, Cabibbo G, Caturelli E, Di Marco M, Azzaroli F, Brunetto MR, Raimondo G, Vidili G, Guarino M, Gasbarrini A, Campani C, Svegliati-Baroni G, Giannini EG, Mega A, Masotto A, Rapaccini GL, Magalotti D, Sacco R, Nardone G, Farinati F; Italian Liver Cancer (ITA.LI.CA) group. Pelizzaro F, et al. Liver Int. 2023 Dec;43(12):2762-2775. doi: 10.1111/liv.15719. Epub 2023 Sep 27. Liver Int. 2023. PMID: 37753540
Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors.
Stefanini B, Bucci L, Santi V, Reggidori N, Rampoldi D, Lani L, Granito A, Sangiovanni A, Cabibbo G, Farinati F, Campani C, Foschi FG, Svegliati-Baroni G, Raimondo G, Gasbarrini A, Mega A, Biasini E, Sacco R, Morisco F, Caturelli E, Vidili G, Azzaroli F, Giannini EG, Rapaccini GL, Brunetto MR, Masotto A, Nardone G, Di Marco M, Magalotti D, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group. Stefanini B, et al. Dig Liver Dis. 2022 Nov;54(11):1563-1572. doi: 10.1016/j.dld.2022.07.003. Epub 2022 Jul 27. Dig Liver Dis. 2022. PMID: 35906166
112 results